ARTELO BIOSCIENCES, INC.
ARTL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ARTL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARTL
Artelo Biosciences is a clinical-stage biopharmaceutical company focused on developing therapeutics that modulate lipid signaling, including the endocannabinoid system, with its lead candidate ART27.13 currently in Phase 2 trials for cancer-related anorexia.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Artelo Biosciences is a clinical-stage biopharmaceutical company focused on developing therapeutics that modulate lipid signaling, including the endocannabinoid system, with its lead candidate ART27.13 currently in Phase 2 trials for cancer-related anorexia.
- Lead candidate ART27.13 is a peripherally acting cannabinoid receptor agonist being studied in a Phase 2 trial (CAReS) for cancer-related anorexia, with initial data expected in Q3 2025 [sec_mda · as of 2025-08-13].
- As of June 30, 2026, Artelo reported cash and equivalents of $4.2M, shareholders' equity of $2.9M, and a net loss of $2.4M for the quarter [sec].
- The company does not plan to internally fund a Phase 3 trial for ART27.13 and believes a licensing transaction is the most value-accretive path forward [sec · filed 2025-09-03].
- Artelo has an ATM sales agreement from May 2026 to sell up to $6.53M of common stock, with net proceeds of $354 from 386,668 shares sold between June 30 and August 11, 2026 [sec_mda · as of 2026-08-12].
What works
- ART27.13 has a supportive clinical profile from Phase 1b, and the company is on track to report Phase 2 data in Q3 2025, which could validate its therapeutic potential [sec · filed 2025-09-03] [sec_mda · as of 2025-08-13].
- Management has experience developing, commercializing, and partnering ethical pharmaceutical products, including first-in-class therapeutics [sec_mda · as of 2026-05-14].
- The company retains the option to internally develop and commercialize programs while also exploring collaborations to maximize stockholder value [sec_mda · as of 2026-08-12].
What to weigh
- Artelo has not generated any revenue to date and expects expenses to increase substantially as it advances its pipeline [sec_mda · as of 2026-02-24].
- As of December 31, 2025, cash and investments were only $0.6 million, raising substantial doubt about the company's ability to continue as a going concern [sec_mda · as of 2026-02-24].
- The company is dependent on a licensing transaction or additional financing to fund a Phase 3 trial, creating significant uncertainty [sec · filed 2025-09-03].
- Recent ATM sales have generated only minimal net proceeds ($354), indicating limited near-term capital from that source [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Artelo does not plan to internally fund a Phase 3 trial for ART27.13 and sees licensing as the best path.
“the Company does not plan to internally fund a Phase 3 trial and believes a licensing transaction represents the most value-accretive path forward for stockholders.”
SEC filings · September 3, 2025
Initial Phase 2 data for ART27.13 is expected in Q3 2025.
“We are on track to report initial data from the Phase 2 CAReS study of ART27.13, its peripherally acting cannabinoid receptor agonist, in Q3 2025.”
SEC MD&A · August 13, 2025
As of December 31, 2025, cash and investments were $0.6 million, with going concern uncertainty.
“As of December 31, 2025, we had cash, cash equivalents, and investments of $0.6 million.”
SEC MD&A · February 24, 2026
Artelo has not generated any revenue and expects increasing expenses.
“To date, we have not generated any revenue and we may not generate any revenue from the sale of products or from other sources in the near future. We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities”
SEC MD&A · February 24, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — As of Dec 31, 2025, only $0.6M cash; substantial doubt about ability to continue [sec_mda · as of 2026-02-24]
- No revenue and rising costs — No product revenue to date; expenses expected to increase substantially [sec_mda · as of 2026-02-24]
- Dependence on licensing deal — Phase 3 not internally funded; success hinges on finding a partner [sec · filed 2025-09-03]
- Limited ATM proceeds — ATM raised only $354 net from 386,668 shares sold [sec_mda · as of 2026-08-12]
What to watch
- Initial Phase 2 data from the CAReS study of ART27.13, expected in Q3 2025 [sec_mda · as of 2025-08-13].
- Any licensing or partnership transaction for ART27.13, which the company views as the most value-accretive path [sec · filed 2025-09-03].
- Cash runway and potential need for additional financing given the low cash balance and going concern warning [sec_mda · as of 2026-02-24].
- Progress of the FABP5 inhibitor program and any preclinical or clinical updates [sec_mda · as of 2025-08-13].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run ARTELO BIOSCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARTELO BIOSCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
2.5 months
D/E 0.29
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$400K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 20,258 | $154K |
| kathmere capital management, llc | 13,250 | $100K |
| jane street group, llc | 13,079 | $99K |
| vanguard fiduciary trust co | 3,139 | $24K |
| citigroup inc | 3,076 | $23K |
| rothschild investment llc | 2 | $15 |
| cwm, llc | 1 | $8 |
| osaic holdings, inc. | 1 | $7 |
Short Interest
as of May 20, 2026- % of float
- 6.7%
- Days to cover
- 0.0
- Shares short
- 62,523
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARTL short interestGovernance
Frequently asked questions
What is the AI investment thesis for ARTELO BIOSCIENCES, INC.?
Artelo Biosciences is a clinical-stage biopharmaceutical company focused on developing therapeutics that modulate lipid signaling, including the endocannabinoid system, with its lead candidate ART27.13 currently in Phase 2 trials for cancer-related anorexia.
Who is the CEO of ARTELO BIOSCIENCES, INC.?
Mr. Gregory D. Gorgas M.B.A. is the chief executive officer of ARTELO BIOSCIENCES, INC. (ARTL).
Where is ARTELO BIOSCIENCES, INC. headquartered?
ARTELO BIOSCIENCES, INC. (ARTL) is headquartered in Solana Beach, CA, United States.
What therapeutic areas does ARTELO BIOSCIENCES, INC. focus on?
ARTELO BIOSCIENCES, INC. develops therapies across Oncology, Neurology, Immunology, Pain, Dermatology, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.